长三角区域内的技术、人才、政策工具等关键要素，将如何推动生物医药产业的跨域融合？ 从长三角国际科创协同角度看，生物医药产业将如何发展、持续发力？ 日前举行的中央经济工作会议明确"建设北京（京津冀）、上海（长三角）、粤港澳大湾区国际科技创 新中心""将上海国际科创中心扩围至长三角"等，为跨域产业协同锚定了战略支点。作为沪苏浙皖重点 布局的世界级研发、制造集群，生物医药产业规模现已突破1.2万亿元，约占全国该产业规模总量的三 分之一。下一步，相关技术、人才、政策工具等关键要素，将如何持续推动该产业的跨域融合？ 区域内如何进行要素配置与优化 业内人士称，科技创新是未来我国很长一段时期内发展产业新动能的着力点，而将国际创新中心的辐射 范围从上海这一超大型城市"扩围"到长三角各城市群，则代表着未来将有更多的科创资源在进一步整合 下，以科学、精准、规范的方式溢出到城市群内的其他城市或地区。 产业策源的核心是技术要素。上海技术交易所总裁颜明峰为第一财经解读称，面向长三角区域，应围绕 技术资源的配置与畅通流动来部署工作，"从技术资源权属来看，谁的成果、怎样的成果、成果如何在 应用过程中实现更好价值等，这些就需要完整的科技成果 ...

Core Viewpoint - The phase of broad increases in the innovative drug sector may be over, and the next two years will be a critical period for differentiation among innovative drug companies, making selective stock picking and focusing on true leaders a more suitable investment strategy [1] Group 1: Investment Strategy - The company will continue to focus on domestic commercialization and international expansion, prioritizing companies that excel in both areas rather than solely betting on business development (BD) transactions [1] - Valuations driven solely by BD are considered fragile, necessitating a careful assessment of associated risks [1] - The market tends to factor in potential total value (including milestone payments) into stock prices at the announcement of BD transactions, but the realization of milestone payments is uncertain and depends on clinical and regulatory success [1] Group 2: Sector Outlook - The company is optimistic about specific segments within innovative drugs, including Antibody-Drug Conjugates (ADC), multi-antibodies, cell and gene therapy, and autoimmune products [2] - Beyond innovative drugs, the company also sees potential in medical devices, Contract Research Organizations (CRO), and medical services [2] - The medical device sector is expected to experience significant growth in orders and inventory digestion due to increased procurement data amid a replacement trend [2] - The CRO sector is likely to benefit from the global shift towards research outsourcing, maintaining steady growth [2] - Economic recovery is anticipated to boost demand for medical services, particularly in high-end and specialized medical services [2]

Core Insights - The 2025 International Biopharmaceutical Industry Innovation Forum highlighted the establishment of multiple key projects in Beijing Economic-Technological Development Area (also known as Beijing E-Town), marking it as a significant hub for the biopharmaceutical industry in China [1][4] - Major international and domestic pharmaceutical companies are investing in the BioPark, with Johnson & Johnson planning to build Asia's first innovation center and GE Healthcare establishing the second-largest medical equipment R&D center globally [1][2] Group 1: Key Projects and Developments - The BioPark will host several first-of-their-kind projects, including a medical device training center and a digital innovation center by Johnson & Johnson, and a medical imaging equipment innovation incubator by GE Healthcare [1][2] - The National AI Application Pilot Base for the medical field will be the largest in the country, focusing on biopharmaceutical manufacturing and providing various common service capabilities [2] - The establishment of the National Medical Products Administration's review center in the Beijing-Tianjin-Hebei region aims to enhance innovation efficiency for local pharmaceutical companies [2] Group 2: Ecosystem and Support Mechanisms - The "seven-in-one" industrial ecosystem in Beijing E-Town integrates various elements such as industry, policy, research, hospitals, finance, and services to drive development [3] - A new 2.0 version of the pharmaceutical health industry support policy was released, focusing on innovative drugs and high-end medical equipment, providing comprehensive support for enterprises [3] - A total of 50 billion yuan has been allocated for a biotechnology and health industry fund, alongside other funds to support high-quality development in the biopharmaceutical sector [3] Group 3: Future Outlook - With over 5,000 biopharmaceutical companies, Beijing E-Town is set to enhance its global innovation capabilities, aiming for a pharmaceutical health industry output value exceeding 120 billion yuan by 2027 [4] - The rapid establishment of key projects, such as AstraZeneca's $2.5 billion investment in a global strategic R&D center, exemplifies the "E-Town speed" in project execution [3]

Core Viewpoint - The article emphasizes that Kanglong Chemical has established itself as a leading global drug research and development service enterprise, with significant growth potential across its various service segments, including laboratory services, small molecule CDMO, clinical CRO, and large molecule and cell gene therapy services [3][4][5]. Group 1: Laboratory Services - The laboratory services segment is the most competitive and currently the primary source of revenue and profit for the company, with expectations for rapid growth driven by competitive advantages in compound design and synthesis [3]. - The biological science services are anticipated to leverage the existing customer base from laboratory chemistry services, leading to sustained high growth in both customer numbers and performance [3]. Group 2: CMC (Small Molecule CDMO) Services - The CMC services are expected to experience rapid growth due to a burgeoning client base and the successful conversion of commercial orders, with a significant increase in the proportion of process validation and commercial orders expected by the first half of 2025 [4]. - The company has established four FDA-approved API commercial production bases across China, the UK, and the US, enabling it to provide innovative drug raw material production solutions globally [4]. Group 3: Clinical CRO Services - The company has completed the establishment of an integrated global clinical CRO service platform, which is expected to enhance efficiency and profitability as industry conditions improve [4]. - The synergy between clinical CRO, preclinical CRO, and CDMO services is anticipated to strengthen further, contributing to accelerated performance [4]. Group 4: Large Molecule and Cell Gene Therapy Services - The company is rapidly advancing its capabilities in large molecule and cell gene therapy services through external resource integration and personnel recruitment, with projected revenue growth of around 10% over the next three years [5]. - This segment is expected to gradually reduce losses, opening up greater long-term growth opportunities for the company [5]. Group 5: Investment Recommendations - The projected net profits for the company from 2025 to 2027 are estimated at 1.689 billion, 1.959 billion, and 2.257 billion yuan, with adjusted net profits of 1.750 billion, 2.122 billion, and 2.438 billion yuan, reflecting year-on-year growth rates of 8.9%, 21.2%, and 14.9% respectively [5]. - The current stock price corresponds to PE ratios of 36, 31, and 27 for 2025-2027, with a recommendation for a higher valuation level based on the company's growth prospects and competitive advantages in the CXO industry [5].

Core Viewpoint - The Jiangsu Wuxi Biopharmaceutical Industry Special Fund aims to promote the development of strategic emerging industries in Jiangsu Province, with a total scale of 4 billion yuan [1]. Group 1: Fund Structure and Investment Strategy - The fund is established in collaboration with Wuxi City to support the integration and development of strategic emerging industry clusters [1]. - Investment methods include setting up sub-funds or direct project investments, with direct investments generally not exceeding 30% of the actual investment amount of the special fund [1]. - The special fund's contribution to sub-funds will not exceed 30% of the sub-fund's total size, and investments in individual direct projects will not exceed 20% of the total paid-in capital of the special fund [1]. Group 2: Investment Focus Areas - The fund primarily invests in pharmaceuticals (including innovative drugs, high-end raw materials, traditional Chinese medicine, cell gene therapy, synthetic biology, etc.), medical devices (including in vitro diagnostic reagents and supporting instruments), and supportive medical industries (including research instruments, synthetic biology, CXO, new medical infrastructure, MAH platform companies, etc.) [2]. - Additional focus areas include consumer healthcare and improving national health quality (including health management, medical aesthetics, special medical foods, and functional foods), as well as AI in pharmaceuticals [2].